Protein design market seen reaching $15.71B by 2030 on AI push

The protein design and engineering market is at an inflection point driven by convergence of AI advances and therapeutic demand. The market's projected growth from $7.62 billion in 2025 to $15.71 billion by 2030—a sustained CAGR of roughly 15.5%—reflects a sector-wide shift toward computational and AI-enabled drug discovery. This acceleration is not solely a result of new technology; it reflects maturation of supporting disciplines: recombinant DNA technologies, structural biology research tools, and molecular biology methodologies have created the infrastructure upon which AI-driven protein design platforms now operate.

The market's expansion is anchored in three interconnected trends. First, AI-powered drug discovery platforms are reducing cycle time and cost in protein optimization. Second, pharmaceutical companies are investing heavily in precision therapeutics and personalized medicine, both of which depend on tailored protein engineering. Third, synthetic biology adoption across the life sciences enables broader access to engineered biologics and custom biomaterials. These factors reinforce each other: better computational tools attract more R&D investment; more investment accelerates tool adoption; broader adoption drives down costs and lowers barriers to entry for smaller organizations.